ArcticZymes AS has received a Notice of Allowance for the United States Patent Application No. 14/036459 further covering patentable subject matter of its heat-labile dsDNase product.
With the approval of the new patent in the USA, ArcticZymes strengthens its rapidly growing intellectual property portfolio. The patent extends protection in the USA to the nucleic acid sequence of the heat-labile dsDNase. This includes a method of isolation and purification of the expressed sequence and subsequent incorporation into kit based technologies. This complements earlier patent protection granted in 2013, which covers amongst others the dsDNase itself, methods for removing contaminations from a sample reaction, as well as kits or compositions comprising the dsDNase.
“This latest patent approval strengthens the overall commercial potential for the innovative HL-dsDNase product in the USA. Furthermore, it supports our commercial efforts with Business-to-business partners.” says Managing Director, Jethro Holter at ArcticZymes AS.
For additional information contact:
Jethro Holter, Managing Director, +47 46 85 91 46, jh@azdev.wpengine.com